Effect of a pharmacist-managed hypertension program on health system costs: An evaluation of the study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN)

Pharmacotherapy

Volumn 32, Issue 6, 2012, Pages 527-537

  Houle, Sherilyn K D ^a   Chuck, Anderson W ^c   McAlister, Finlay A ^a,b   Tsuyuki, Ross T ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cost; Economics; Hypertension; Pharmaceutical care; Pharmaceutical services; Pharmacist

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE DURATION; HEALTH CARE COST; HEALTH PROGRAM; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PHARMACIST ATTITUDE; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 84864603405     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01097.x     Document Type: Article

References (35)

1. Wilkins K, Campbell NR, Joffres MR, et al. Blood pressure in Canadian adults. Health Rep 2010;21(1): 37-46. Statistics Canada, Catalogue no. 82-003-XPE
2. Centres for Disease Control and Prevention. Hypertension and elevated blood pressure among persons 20 years of age and over, by selected characteristics: United States. Available from http://www.cdc.gov/nchs/hus.htm. Accessed June 14, 2011
3. Centres for Disease Control and Prevention. High Blood Pressure Frequently Asked Questions. Available from http://www. cdc.gov/bloodpressure/ faqs.htm. Accessed November 2, 2011
4. Heart and Stroke Foundation of Canada. Statistics. Available from http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics. htm. Accessed November 2, 2011
5. McLean DL, McAlister FA, Johnson J, et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med 2008;168(21):2355-61
6. Santschi V, Chiolero A, Burnand B, et al. Impact of pharmacist care in the management of cardiovascular disease risk factors. Arch Intern Med 2011;171(16):1441-53
7. Vaananen MH, Lyles A, Airaksinen M. The symptom mitigation path of mobile community residents: Community pharmacy's role. Health Policy 2009;89:14-25
8. Canadian Hypertension Education Program. CHEP Recommendations for the Management of Hypertension. 2012. Available from http://www.hypertension.ca/ images/stories/dls/2012gl/2012CompleteCHEPRecommendationsEN.pdf. Accessed April 9, 2012
9. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
10. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
11. Arnold JMO, Yusuf S, Young J, et al. Prevention of heart failure in patients in the health outcomes prevention evaluation (HOPE) study. Circulation 2003;107:1284-90
12. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive vascular disease. J Am Coll Cardiol 2000;36:438-43
13. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
14. Teo K, Burton J, Buller C, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-54
15. Staessen J, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension in Europe. Lancet 1997;350:757-64
16. Brenner B, Cooper M, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
17. Lithell H, Hansson L, Skogg I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomised double-blind intervention trial. J Hypertens 2003;21:875-86
18. Pitt B, Byington R, Furberg C, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-10
19. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
20. Statistics Canada. Canadian Consumer Price Index, by Province. Available from http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ161j-eng. htm. Accessed April 9, 2012
21. Canadian Institute for Health Information. The cost of acute care hospital stays by medical condition in Canada, 2004-2005. Ottawa, ON: CIHI, 2008
22. McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation 1973;48:1104-11
23. Government of Alberta. Alberta Wage and Salary Survey. 2011. Available from http://alis.alberta.ca/wageinfo/Content/RequestAction.asp?aspAction= GetWageDetail&format=html&RegionID=20&NOC=3131. Accessed April 9, 2012
24. Isetts BJ, Schondelmeyer SW, Artz MB, et al. Clinical and economic outcomes of medication therapy management services: The Minnesota experience. J Am Pharm Assoc 2008;48:203-11
25. Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME Study). J Gen Intern Med 2005;20:1091-6
26. Bunting BA, Smith BH, Sutherland SE. The Asheville project: Clinical and economic outcomes of a community-based longterm medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc 2008;48:23-31
27. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA 2006;296(21):2563-71
28. Carter BL, Doucette WR, Franciscus CL, Ardery G, Kluesner KM, Chrischilles EA. Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention. Pharmacotherapy 2010;30(3):228-35
29. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysisof 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
30. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007;41:1770-8
31. Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control. Arch Intern Med 1984;144:1159-62
32. Borenstein JE, Graber G, Saltiel E, et al. Physician-pharmacist comanagement of hypertension: A randomized, comparative trial. Pharmacotherapy 2003;23(2):209-16
33. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy 2001;21(11):1337-44
34. Chan P, Grindrod KA, Bougher D, et al. A systematic review of remuneration systems for clinical pharmacy care services. Can Pharm J 2008;141(2):102-12
35. Charrois TL, McAlister FA, Cooney D, et al. Improving hypertension management through pharmacist prescribing: The rural Alberta clinical trial in optimizing hypertension (Rural RxACTION): Trial design and methods. Implement Sci 2011;6: 94.